In-hospital risk factors for type1 myocardial infarction (MI) have been extensively investigated, but risk factors for type2 MI are still emerging. Moreover, type2 MI remains an underdiagnosed and under-researched condition. Our aim was to assess survival rates after type2 MI and to analyze the risk factors for patient prognosis after hospitalization. We conducted a retrospective database analysis of patients with MI diagnosis who were treated in Vilnius University Hospital Santaros Klinikos. A total of 6495 patients with the diagnosis of MI were screened. The primary study endpoint was long-term all-cause mortality. The predictive value of laboratory tests was estimated including blood hemoglobin, Ddimer, creatinine, brain natriuretic peptide (BNP), C-reactive protein (CRP), and troponin levels. Out of all the patients diagnosed with MI there were 129 cases of type2 MI (1.98%). Death rate almost doubled from 19.4% at 6months to 36.4% after 2years of follow-up. Higher age and impaired kidney function were risk factors for death both during hospitalization and after 2years of follow-up. Lower hemoglobin (116.6 vs. 98.9g/L), higher creatinine (90 vs. 161.9μmol/L), higher CRP (31.4 vs. 63.3mg/l), BNP (707.9 vs. 2999.3ng/L), and lower left ventricle ejection fraction were all predictors of worse survival after 2years of follow-up. Preventive medication during hospitalization can decrease the mortality risk: angiotensin-converting enzyme inhibitor (ACEi) (HR 0.485, 95%CI 0.286-0.820) and statins (HR 0.549, 95%CI 0.335-0.900). No significant influence was found for beta blockers (HR 0.662, 95%CI 0.371-1.181) or aspirin (HR 0.901, 95%CI 0.527-1.539). There is significant underdiagnosis of type2 MI (1.98% out of all MIs). If the patient is prescribed a preventive medication like ACEi or statins, the mortality risk is lower. Increased awareness of elevation of laboratory results could help to improve the treatment of these patients and identify the most vulnerable groups.